Ustekinumab Is Associated with Real-World Long-Term Effectiveness and Improved Health-Related Quality of Life in Crohn's Disease

被引：0
作者：
Anders Forss
Mark Clements
Pär Myrelid
Hans Strid
Charlotte Söderman
Agnieszka Wagner
David Andersson
Fredrik Hjelm
Ola Olén
Jonas Halfvarson
Jonas F. Ludvigsson
机构：
[1] Karolinska Institutet,Department of Medical Epidemiology and Biostatistics
[2] Linköping University Hospital,Department of Biomedical and Clinical Sciences, Division of Surgery
[3] Linköping University,Department of Internal Medicine
[4] Södra Älvsborg Hospital,Medical Department
[5] Capio St Göran Hospital,Department of Internal Medicine
[6] Blekinge Hospital,Department of Internal Medicine
[7] Danderyd University Hospital,Clinical Epidemiology Division, Department of Medicine Solna
[8] Janssen Cilag AB,Sachs’ Children and Youth Hospital
[9] Karolinska Institutet,Department of Gastroenterology, Faculty of Medicine and Health
[10] Stockholm South General Hospital,Department of Paediatrics
[11] Örebro University,Department of Medicine
[12] Örebro University Hospital,undefined
[13] Columbia University College of Physicians and Surgeons,undefined
来源：
Digestive Diseases and Sciences | 2023年 / 68卷
关键词：
Crohn’s disease; Inflammatory bowel disease; Observational study; Ustekinumab;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：65 / 76
页数：11
相关论文
共 99 条
[1]  
Baumgart DC(2012)Crohn's disease Lancet 380 1590-1605
[2]  
Sandborn WJ(2020)Colorectal cancer in Crohn's disease: a Scandinavian population-based cohort study Lancet Gastroenterol. Hepatol. 5 475-484
[3]  
Olen O(2020)Mortality in adult-onset and elderly-onset IBD: a nationwide register-based cohort study 1964–2014 Gut. 69 453-461
[4]  
Erichsen R(2020)Healthcare use, work loss and total costs in incident and prevalent Crohn's disease and ulcerative colitis: results from a nationwide study in Sweden Aliment Pharmacol. Ther. 52 655-668
[5]  
Sachs MC(2018)Incidence and treatment of patients diagnosed with inflammatory bowel diseases at 60 years or older in Sweden Gastroenterology. 154 518-528
[6]  
Olen O(2014)Temporal trends in non- stricturing and non-penetrating behaviour at diagnosis of Crohn's disease in Örebro, Sweden: a population-based retrospective study J. Crohns Colitis 8 1653-30
[7]  
Askling J(2014)Optimizing anti-TNF treatments in inflammatory bowel disease Autoimmun. Rev. 13 24-366
[8]  
Sachs MC(2010)Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases: definitions, frequency and pharmacological aspects J. Crohns Colitis. 4 355-197
[9]  
Khalili H(2015)Role for therapeutic drug monitoring during induction therapy with TNF antagonists in IBD: evolution in the definition and management of primary nonresponse Inflamm. Bowel Dis. 21 182-51
[10]  
Everhov AH(2016)Systematic review: predicting and optimising response to anti-TNF therapy in Crohn's disease - algorithm for practical management Aliment Pharmacol. Ther. 43 30-767
12345678910